DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/77bfe1/influenza_vaccine) has announced the addition of Decision Resources, Inc.'s new report "Influenza Vaccine Manufacturing: Can New Technologies Open the Production Bottleneck?" to (…)
[Read article]
[Source: Business Wire]
Background: Healthcare professionals have a responsibility to help each woman select the most appropriate hormonal contraceptive according to her personal preferences, needs and circumstances. Objective: To assess attitudes, awareness, compliance and preferences of hormonal (…)
[Read article]
[Source: NCBI PubMed]
PARP-1 inhibitors have emerged as a promising therapeutic class of compounds, and numerous PARP inhibitors, including iniparib (BiPar Sciences Inc/sanofi-aventis), olaparib (AstraZeneca plc), veliparib (Abbott Laboratories), PF-1367338 (Pfizer Inc), MK-4827 (Merck & Co Inc) and (…)
[Read article]
[Source: NCBI PubMed]
(1S,5R)-2-{[(4S)-azepan-4-ylamino]carbonyl}-7-oxo-2,6-diazabicyclo[3.2.0] heptane-6-sulfonic acid (Compound 1) is a beta-lactamase inhibitor for intravenous administration. The objective of this preformulation study was to determine the most appropriate form of the API for (…)
[Read article]
[Source: NCBI PubMed]
During the last several decades, the scientific and ethics communities have addressed important ethical issues in medical research, resulting in the elaboration and adoption of concepts, guidelines, and codes.Ethical issues in the conduct of Multiregional Clinical Trials have (…)
[Read article]
[Source: NCBI PubMed]
Calculation of chromatographic enantioselectivity (alpha) is critically important in enantioselective chromatographic method development studies. The fact that alpha can only be calculated from isocratic elution conditions, whereas gradient elution conditions are predominantly (…)
[Read article]
[Source: NCBI PubMed]
J Med Chem. |-| Stanton MG, Colletti SL. |-| Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486.
[Read article]
[Source: NCBI PubMed]
Geneva, Switzerland, 8 September 2010 - Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced today that it has been awarded a $900,000 grant from The Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of (…)
[Read article]
[Source: BioSpace]
Sep 08, 2010 (NORDIC BUSINESS REPORT via COMTEX) -8 September 2010 - Swedish drug developer Karo Bio AB (STO: KARO) has been notified by its US partner Merck & Co Inc (NYSE: MRK | PowerRating) that it decided to discontinue the development of their joint drug candidate MK-6913 (…)
[Read article]
[Source: BioSpace]
GENEVA, SWITZERLAND-(Marketwire - September 7, 2010) - Addex Pharmaceuticals / Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's Disease processed and transmitted by Hugin AS. The issuer is solely responsible for the (…)
[Read article]
[Source: Marketwire]
MECHELEN, BELGIUM-(Marketwire - September 07, 2010) - Galapagos NV (Euronext: GLPG) announced today that its Board of Directors has appointed Mr. Howard Rowe as an Independent Director of the Company. Furthermore, Galapagos announced a capital increase arising from employee (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f7e7a7/epigenetics_therap) has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/60383e/thailand_pharmaceu) has announced the addition of the "Thailand Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Thailand Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for (…)
[Read article]
[Source: Medical News Today]
WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST (asenapine) (…)
[Read article]
[Source: Business Wire]
Merck & Co and partner Cardiome Pharma Corp have been granted marketing approval by European regulators for the intravenous formulation of their anti-arrhythmic Brinavess. The European Union, Iceland and Norway have given the green light to Brinavess (vernakalant) for the rapid (…)
[Read article]
[Source: BioSpace]
AMSTERDAM, Sept 2 (Reuters) - U.S. drugmaker Merck & Co (MRK.N) has postponed the closure of some of its Dutch operations while it negotiates with executives and workers on potential alternatives, including a sale of the R&D site.
[Read article]
[Source: BioSpace]
GENEVA, SWITZERLAND-(Marketwire - September 02, 2010) - Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer's disease model processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Allosteric modulation (…)
[Read article]
[Source: BioSpace]
Bloomberg - The 30-year-long search for a cure for AIDS, the world s deadliest viral infection, may get a renewed boost from an unlikely source: a little-used Merck & Co. cancer drug.
[Read article]
[Source: BioSpace]
VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ:CRME - News) today announced that it has earned a US$30 million milestone payment from its collaboration with Merck (known as MSD outside the United States and Canada), through an affiliate. The milestone (…)
[Read article]
[Source: BioSpace]
WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST (asenapine) (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
WHITEHOUSE STATION, N.J. & VANCOUVER, British Columbia-(BUSINESS WIRE)-Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) today announced that the intravenous (IV) formulation of BRINAVESS ¢ (vernakalant) (…)
[Read article]
[Source: Business Wire]
WHITEHOUSE STATION, N.J. U.S.A. & VANCOUVER, British Columbia-(BUSINESS WIRE)-MSD (known in the US and Canada as Merck) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) today announced that the intravenous (IV) formulation of BRINAVESS ¢ (vernakalant) has been (…)
[Read article]
[Source: Business Wire]
MONTREAL, CANADA-(Marketwire - September 01, 2010) - Theratechnologies (TSX: TH) announced today the appointment of Mr. John-Michel T. Huss as President and Chief Executive Officer of the Company. Mr. Huss will assume his responsibilities in the coming months. Until recently, (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/23871e/nigeria_pharmaceut) has announced the addition of the "Nigeria Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Nigeria Pharmaceuticals and Healthcare Report (…)
[Read article]
[Source: Business Wire]
MILL VALLEY, Calif. - March 26, 2010 - BioCision LLC today announced that it has signed a European distribution agreement with SERVA Electrophoresis, a global supplier of reagents for scientific research. SERVA Electrophoresis will sell BioCision s entire portfolio of (…)
[Read article]
[Source: BioSpace]
MILL VALLEY, Calif. February 11, 2010 - BioCision LLC, the CoolRack ¢ company, announced today that it has entered into a distribution agreement with Biophoretics, a developer and distributor of advanced tools for scientific research. Biophoretics will sell BioCision s entire (…)
[Read article]
[Source: BioSpace]
MILL VALLEY, Calif. - BioCision LLC, the CoolRack ¢ company, announced today that is has reached an agreement with Capital Biosciences Inc. for the distribution of BioCision's products, which standardize the handling and processing of temperature-sensitive samples. Capital (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f02991/stakeholder_opinio) has announced the addition of the "Stakeholder Opinions: Sexually Transmitted Diseases - An Underestimated Threat Lacking Interventions to Prevent Transmission" (…)
[Read article]
[Source: Business Wire]
MILL VALLEY, Calif., March 31 /PRNewswire/ - BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc. (www.us.biohit.com). Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, (…)
[Read article]
[Source: BioSpace]
STOCKHOLM, SWEDEN-(Marketwire - August 30, 2010) - Portola Pharmaceuticals, Inc. today announced results from the Phase 2 INNOVATE-PCI study of its investigational antiplatelet drug, elinogrel, the only competitive, reversible direct-acting P2Y12 ADP receptor antagonist. (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/364cde/women's_infertilit) has announced the addition of GlobalData 's new report "Women's Infertility - Pipeline Assessment and Market Forecasts to 2017" to their offering. Women's (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3373b4/us_pharmaceutical) has announced the addition of the "US Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed decelerating growth rates in the years (…)
[Read article]
[Source: Business Wire]
A general method for the enantioselective hydrogenation of protected allylic amine derivatives is described. This procedure relies on the generation of a cationic ruthenium complex with the axially chiral ligand (-)-TMBTP. The utility is highlighted by the highly (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Biomarker research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)
[Read article]
[Source: Business Wire]
GENEVA, SWITZERLAND-(Marketwire - August 25, 2010) - Addex Pharmaceuticals / Addex Partner Completes ADX71149 Phase I Program processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 25 August 2010 - (…)
[Read article]
[Source: BioSpace]